Rat HCC tumor cells transfected with CEACAM1a-4L displayed a significant decrease in tumor formation, progression, and burden compared to rat HCC cells transfected with CEACAM1b-4S and the negative control group, suggesting that CEACAM1 splice-switching therapy may inhibit HCC [96]. The gene discussed is CEACAM1; the disease is hepatocellular carcinoma.